LEADER 01760oam  2200493   450 
001 9910708356803321
005 20180323151259.0
035   $a(CKB)3460000000106669
035   $a(OCoLC)852784169$z(OCoLC)654992341$z(OCoLC)760056613$z(OCoLC)1012086687$z(OCoLC)1022024867
035   $a(EXLCZ)993460000000106669
100   $a20130713d2001      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aContinuing concerns over imported pharmaceuticals $ehearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, first session, June 7, 2001
210  1$aWashington :$cU.S. Government Printing Office,$d2001.
215   $a1 online resource (iii, 191 pages) $cillustrations
300   $a"Serial No. 107-30."
320   $aIncludes bibliographical references.
517   $aContinuing concerns over imported pharmaceuticals 
606   $aDrugs$xInspection$zUnited States
606   $aDrug adulteration$xGovernment policy$zUnited States
606   $aPharmaceutical industry$zUnited States$xQuality control
615  0$aDrugs$xInspection
615  0$aDrug adulteration$xGovernment policy
615  0$aPharmaceutical industry$xQuality control.
801  0$bOCLCE
801  1$bOCLCE
801  2$bOCLCO
801  2$bOCLCA
801  2$bOCLCQ
801  2$bOCLCO
801  2$bOCLCF
801  2$bOCLCA
801  2$bOCLCQ
801  2$bNJR
801  2$bOCLCQ
801  2$bGPO
906   $aBOOK
912   $a9910708356803321
996   $aContinuing concerns over imported pharmaceuticals$93468668
997   $aUNINA